Skip to main content
    I

    IGC Pharma, Inc. (IGC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $0.19
    +0.01 (+5.03%)

    Market Cap: $19.54M

    Last updated: Nov 06, 2026 at 4:43 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    75%(9/12)
    Avg Surprise
    -67.31%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.02
    Range$-0.02 - $-0.02
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$-0.03+20.0%
    60d ago$-0.03+20.0%
    30d ago$-0.03+20.0%
    7d ago$-0.020.0%
    Current$-0.02
    Revenue Consensus
    $96000
    Range$96000 - $96000
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.02
    Range$-0.02 - $-0.02
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$-0.03+20.0%
    60d ago$-0.03+20.0%
    30d ago$-0.03+20.0%
    7d ago$-0.020.0%
    Current$-0.02
    Revenue Consensus
    $280000
    Range$280000 - $280000
    1 analysts
    Last 12 of 39 reported quarters and 3 upcoming estimates
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Mar 27EST
    		-$-0.03$-0.03 - $-0.03--1--
    Dec 26EST
    		-$-0.02$-0.02 - $-0.02--1
    No revisions (30d)
    		-
    Sep 26EST
    		-$-0.02$-0.02 - $-0.02--1
    No revisions (30d)
    		-
    Jun 26
    Reported Aug 14
    		$-0.03$-0.02$-0.02 - $-0.02-50.00%Miss2
    No revisions (30d)
    		-102.7%
    Mar 26
    Reported Apr 3
    		$-0.02$-0.02$-0.02 - $-0.02+0.00%Beat2
    No revisions (30d)
    		-100.0%
    Dec 25
    Reported Feb 18
    		$-0.02$-0.02$-0.02 - $-0.02+0.00%Beat1
    1
    0
    30d
    		+0.0%
    Sep 25
    Reported Nov 14
    		$-0.02$-0.02$-0.02 - $-0.02+0.00%Beat2
    1
    0
    30d
    		+0.0%
    Jun 25
    Reported Aug 14
    		$-0.01N/A-+50.67%Beat2
    No revisions (30d)
    		+50.7%
    Mar 25
    Reported Jun 27
    		$-0.01$-0.02$-0.02 - $-0.02+50.00%Beat2
    1
    0
    30d
    		+97.5%
    Dec 24
    Reported Feb 14
    		$-0.02$-0.03$-0.03 - $-0.03+33.33%Beat1
    1
    0
    30d
    		+60.0%
    Sep 24
    Reported Nov 12
    		$-0.02$-0.03$-0.03 - $-0.02+33.33%Beat2
    No revisions (30d)
    		+60.0%
    Jun 24
    Reported Aug 8
    		$-0.03$-0.03$-0.03 - $-0.02+0.00%Beat2
    1
    0
    30d
    		+25.0%
    Mar 24
    Reported Jun 24
    		$-0.40$-0.04$-0.04 - $-0.04-900.00%Miss1
    No revisions (30d)
    		-427.0%
    Dec 23
    Reported Feb 14
    		$-0.05$-0.04--25.00%Miss---17.9%
    Sep 23
    Reported Nov 9
    		$-0.05$-0.05-+0.00%Beat---6.8%

    Key Metrics

    Valuation
    P/E Ratio-2.07EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-1051.00%
    ROE-83.30%ROICN/A
    Financial Health
    Debt/Equity0.18xInterest CoverageN/A
    Current Ratio0.39xQuick Ratio0.19x
    Trading Statistics
    Beta0.55Avg Volume516.74K
    52-Week High$0.4052-Week Low$0.18

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.21
    SMA 20$0.23
    SMA 50$0.26
    SMA 200$0.28
    EMA 10$0.21
    EMA 20$0.22
    EMA 50$0.25
    EMA 200$0.28

    MACD

    Line: -0.02Signal: -0.02Hist: -0.00

    ADX

    ADX: 48.8+DI: 4.9-DI: 42.8

    Aroon & PSAR

    Aroon Up12.0
    Aroon Down76.0
    PSAR$0.09

    Bollinger Bands

    Upper Band$0.29
    Lower Band$0.17
    %B Position5162%(Upper)
    Band Width0.24

    RSI (14-Day)

    Neutral
    33.6

    Momentum Oscillators

    Stoch %K62.5
    Stoch %D60.5
    Williams %R-33.1
    ROC (10d)-19.3%
    Momentum-0.05
    CCI (20d)-83.7
    MFI (14d)32.9

    Volatility Measures

    ATR (14d)$0.02(10.8%)
    StdDev (20d)0.03
    Hist Vol76.7%(High)

    Volume Flow

    VWAP$0.19
    OBV84.0M
    AD Line46.6M
    CMF (20d)-0.104

    Volume Metrics

    Avg Vol (20d)540.5K
    Vol Ratio1.0x
    VWMA (20d)$0.22

    Pivot Points

    R3$0.22
    R2$0.21
    R1$0.20
    Pivot Point$0.19
    S1$0.18
    S2$0.17
    S3$0.16

    Advanced Oscillators

    TSI-41.88
    Ultimate Osc60.7
    KST-221.81

    Financial Data

    QuarterSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total Revenue$328,000$265,000$317,000$350,000$191,000$328,000$330,000$257,000$412,000$330,000$295,000$204,000
    Cost of Revenue$267,000$217,000$262,000$306,000$92,000$174,000$176,000$153,000$214,000$176,000$124,000$71,000
    Gross Profit$61,000$48,000$55,000$44,000$99,000$154,000$154,000$104,000$198,000$154,000$171,000$133,000
    Operating Expenses$1.99M$2.83M$2.51M$2.98M$3.00M$2.06M$1.57M$1.98M$1.96M$1.57M$3.06M$5.75M
    R&D$1.01M$1.39M$1.27M$1.48M$1.59M$851,000$997,000$852,000$917,000$997,000$855,000$903,000
    SG&A$979,000$1.44M$1.24M$1.50M$1.41M$1.21M$570,000$1.13M$1.04M$570,000$1.49M$2.23M
    Operating Income$-1,931,000$-2,784,000$-2,458,000$-2,941,000$-2,899,000$-1,905,000$-1,413,000$-1,878,000$-1,760,000$-1,413,000$-2,170,000$-2,998,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$115,000$152,000$0$0$152,000$0$0$0$0$0$715,000$2.59M
    Income Before Tax$-2,046,000$-2,936,000$-2,402,000$-726,000$-1,821,000$-1,599,000$-1,198,000$-1,829,000$-1,717,000$-1,198,000$-2,885,000$-5,589,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-2,046,000$-2,936,000$-2,402,000$-726,000$-1,821,000$-1,599,000$-1,198,000$-1,829,000$-1,717,000$-1,198,000$-2,885,000$-5,589,000
    EBITDA$-1,988,000$-2,880,000$-2,344,000$-662,000$-1,702,000$-1,458,000$-2,341,000$-1,672,000$-1,458,000$-1,044,000$-1,999,000$-2,806,000
    EBIT$-2,046,000$-2,936,000$-2,402,000$-726,000$-1,821,000$-1,599,000$-2,495,000$-1,829,000$-1,599,000$-1,198,000$-2,163,000$-2,966,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IGC

    News

    An experimental Alzheimer's drug has patents in three countries. Its patient study is in final dosing.

    IGC Pharma's experimental Alzheimer's drug candidate, IGC-AD1, has received a Canadian patent, expanding its protection to the U.S., Canada, and Mexico...

    Stock Titan•11/5/26•Bullish

    IGC Pharma, Inc. (IGS1.F) Seasonal returns chart - Yahoo Finance

    The article provides a seasonal returns chart for IGC Pharma, Inc. (IGS1.F) based on average monthly price returns from 2016 to 2026. It shows the stock's current performance with a Frankfurt-delayed quote...

    Yahoo Finance Singapore•10/31/26•Somewhat-Bearish

    IGC Pharma Inc (IGS1.DU) Seasonal returns chart

    This article presents a seasonal returns chart for IGC Pharma Inc (IGS1.DU), showing the average monthly price return for the years 2025-2026. The data is based on a delayed quote from Dusseldorf...

    Yahoo Finance UK•10/31/26•Neutral

    IGS1.MU interactive stock chart | IGC Pharma Inc. R stock - Yahoo Finance

    This page provides an interactive stock chart for IGC Pharma Inc. (IGS1.MU) on the Munich exchange. The stock closed at EUR 0.2200, up 2.80% on October 23. Users can adjust chart ranges, intervals...

    Yahoo Finance Singapore•10/24/26•Neutral

    IGC Pharma, Inc. Estimates – AMEX:IGC

    This article provides an overview of IGC Pharma, Inc. (AMEX: IGC) financial data and analyst estimates available on TradingView. It highlights key financial statements such as income statement, balance sheet...

    TradingView•10/23/26•Neutral

    IGC Valuation and Fair Value

    P/E
    -2.1x
    PEG
    0.0x
    P/B
    3.0x
    See GNG's fair value

    IGC Profitability: Margins, ROIC and FCF

    Operating margin
    -1051.0%
    Net margin
    0.0%
    ROE
    -83.3%

    IGC Competitors

    CompanyTicker
    Nano X Imaging LtdNNOX
    Quoin Pharmaceuticals Ltd DRCQNRX
    TherapeuticsMD IncTXMD
    Cocrystal Pharma IncCOCP
    Immutep Ltd ADRIMMP
    Vyne Therapeutics IncVYNE
    Entero Therapeutics, Inc.ENTO
    Picard Medical, Inc.PMI

    Sector: Healthcare

    IGC Bull Case vs Bear Case

    Bear case

    • IGC's quarterly revenue changed -19.2% year over year.

    IGC Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    14.7%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.02
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    IGC Earnings Date

    IGC reports Nov 13, 2026. The date is confirmed.

    IGC ETF Holders

    GNG tracks 1 ETF that holds IGC.

    1. Vanguard Extended Market Index Fund ETF Shares (VXF), <0.01% of the fund
    Open the ETF Stock Exposure tool for IGC

    See insider activity

    Frequently Asked Questions About IGC

    When does IGC report earnings?

    IGC Pharma, Inc. (IGC) is confirmed to report earnings on Nov 13, 2026.

    Does IGC pay dividends?

    IGC Pharma, Inc. (IGC) does not currently pay a regular dividend.

    What is IGC's market cap?

    IGC Pharma, Inc. (IGC) has a market capitalization of $19.54M with a current stock price of $0.19.

    Related stocks

    Sector: Healthcare

    All stocks starting with I

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In